 |
|
|
| |
ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION
|
| |
| |
Presented at the 23rdInternational AIDS Conference
Reported by Jules Levin
https://go.aws/2yKrAwK
July 06-10, 2020
C. Orkin1, J.-M. Molina2, Y. Yazdanpanah3, C. Chahin Anania4, E. DeJesus5, J. Eron6, S.O. Klopfer7, A Grandhi7, K. Eves7, D. Jackson Rudd7, M.N Robertson7, P. Sklar7, C. Hwang7, G.J. Hanna7, T. Correll7
1Queen Mary University of London, London, United Kingdom, 2St-Louis Hospital and University, Department of Infectious Disease, Paris, France, 3Bichat Hospital, Paris, France, 4Hospital HernánHenríquezAravenaof Temuco, Temuco, Chile, 5Orlando Immunology Center, Orlando, United States, 6Division of Infectious Disease, University of North Carolina, Chapel Hill, North Carolina, United States, 7Merck & Co., Inc., Kenilworth, NJ, United States
|
| |
|
|
|
|
|
